Emergex, a clinical-stage, privately-held biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of 100% synthetic T cell Adaptive Vaccines that harness the body’s natural T cell immune response to destroy pathogen-infected cells in order to provide protection against some of the world’s most pressing health threats: [i] viral infectious diseases, amongst which are Dengue, Coronaviruses, and pandemic Influenza, as well as [ii] serious intracellular bacterial infectious diseases. 

Today’s announcement include details of their adaptive vaccine for Smallpox and Monkeypox, confirmation of their acquisition of MAP Technology and a statement on the manufacturing of their Universal Influenza Vaccine. For more information, click the below buttons to access their recent press releases.

For further information, please contact:

Emergex
Storme Moore-Thornicroft, Executive Director, Phone: +44 (0) 1235 527589
Email: smt@emergexvaccines.com

Robin Cohen, Chief Commercial Officer, Phone: +44 (0) 1235 527589
Email: rc@emergexvaccines.com

Consilium Strategic Communications

Chris Gardner / Ashley Tapp
Phone: +44 (0)20 3709 5700
Email: Emergex@consilium-comms.com